Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    

NOVAVAX, INC.

SummaryChartsNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Novavax : Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2019 | 04:06pm EST

GAITHERSBURG, Md., May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between Novavax and The Bank of New York Mellon Trust Company, N.A., as trustee (Indenture), effective May 10, 2019.

As approved by Novavax’ stockholders at a special meeting held on May 8, 2019, Novavax effected a reverse stock split of its issued and outstanding common stock, par value $0.01 (Common Stock) at a ratio of 1-for-20, effective as of 12:01 a.m. Eastern Time on May 10, 2019 (Reverse Stock Split).

As a result of the Reverse Stock Split and pursuant to Section 14.04(a) of the Indenture, effective May 10, 2019, the conversation rate under the Indenture will be equal to 7.3411 shares of Common Stock per $1,000 principal amount of the Convertible Notes.

As a result of the foregoing adjustment to the conversion rate and pursuant to Section 14.03(d) of the Indenture, effective May 10, 2019, the table setting forth the number of additional shares of Common Stock to be added to the conversion rate for each $1,000 principal amount of Notes in connection with a make-whole adjustment event based on hypothetical stock prices and effective dates pursuant to Section 14.03(e) of the Indenture was adjusted to read as follows:

  Stock Price
Effective Date $111.20 $120.00 $130.00 $136.20 $140.00 $160.00 $200.00 $300.00 $400.00 $500.00 $600.00
January 29, 2016 1.6517 1.5755 1.3668 1.2563 1.1952 0.9315 0.5983 0.2342 0.0979 0.0373 0.0093
February 1, 2017 1.6517 1.6068 1.3859 1.2695 1.2053 0.9302 0.5881 0.2242 0.0918 0.0341 0.0079
February 1, 2018 1.6517 1.6198 1.3862 1.2639 1.1967 0.9113 0.5636 0.2069 0.0823 0.0292 0.0057
February 1, 2019 1.6517 1.6311 1.3803 1.2501 1.1789 0.8802 0.5267 0.1830 0.0697 0.0231 0.0032
February 1, 2020 1.6517 1.6055 1.3357 1.1972 1.1221 0.8124 0.4616 0.1478 0.0530 0.0156 0.0007
February 1, 2021 1.6517 1.5419 1.2458 1.0966 1.0167 0.6962 0.3602 0.1017 0.0341 0.0081 0.0000
February 1, 2022 1.6517 1.3911 1.0532 0.8889 0.8030 0.4796 0.1974 0.0475 0.0157 0.0019 0.0000
February 1, 2023 1.6517 0.9923 0.3512 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
                       

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors:
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
John.woolford@westwicke.com
443-213-0506

Novavax logo

Source: Novavax, Inc.

2019 GlobeNewswire, Inc., source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVAVAX, INC.
11/08NOVAVAX INC : Results of Operations and Financial Condition, Financial Statement..
AQ
11/07NOVAVAX : 3Q Earnings Snapshot
AQ
11/07NOVAVAX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/07Novavax Reports Third Quarter 2019 Financial Results
GL
10/31Novavax to Host Conference Call to Discuss Third Quarter Financial Results on..
GL
10/15Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine..
GL
09/19Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference
GL
09/09NOVAVAX INC : Other Events (form 8-K)
AQ
09/09NOVAVAX : to Present at the H.C. Wainwright 21st Annual Global Investment Confer..
AQ
09/06Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Confe..
GL
More news
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
John J. Trizzino CFO, Treasurer, Chief Business Officer & Senior VP
Gregory M. Glenn President-Research & Development
Louis F. Fries Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.213.04%107
IQVIA HOLDINGS INC.25.12%28 203
LONZA GROUP32.23%25 328
INCYTE CORPORATION47.81%20 245
SEATTLE GENETICS, INC.106.78%20 080
CELLTRION, INC.--.--%18 090